Approximately, 5–22% of NSCLC patients with first- or second-generation EGFR–TKI resistance [18,21] and 5–50% patients with third generation EGFR–TKI resistance harbor MET amplification [22], while MET amplification as a co-driver occurs in 2–11% EGFR-positive treatment-naïve NSCLC patients [23,24]. Here, MET is linked to non-small cell lung carcinoma.